M&A, Data, & Big Approvals Are Defining Diabetes Tech in 2022

Glooko keeps the momentum going in diabetes tech by acquiring Diabnext, to expand its presence in Europe.

Omar Ford

March 16, 2022

2 Min Read
Image courtesy of David Esser / Alamy Stock Photo

It seems as if 2022 is shaping up to be a big year for Diabetes Tech. Several deals, strong data, and product approvals are making the space red hot right now.

Glooko is the latest newsmaker for diabetes tech – as the Palo Alto, CA-based company is quickly hopping back on the M&A trail after the xBird deal in February.

Glooko has acquired Diabnext, a company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can work together to improve health outcomes.

Diabnext, which is based in France, would help expand Glooko’s offerings in Europe.

Diabnext’s mobile app complements Glooko's product portfolio Under the Glooko product umbrella, Diabnext’s technology can significantly increase the number of patients and healthcare providers in the territory and expand remote patient monitoring offerings.

“The addition of Diabnext expands our offerings with a unique platform that can help us better customize the patient experience and improve health outcomes for people with diabetes,” said Russ Johannesson, CEO of Glooko. “Glooko's acquisition of Diabnext further cements our commitment to increase our global presence and continue to drive innovative solutions."

The company said the Diabnext platform will be marketed under the name Glooko XT.

The Diabnext deal comes at a time when there are major developments occurring in the diabetes management space. In the last few months two of the most anticipated devices in the space won approval.

In February, Senseonics won FDA approval for a six-month version of its Eversens Continuous Glucose Management System. Then just a few days ago, Dexcom was awarded CE mark for its G7 CGM system.

And earlier this week, Better Therapeutics announced favorable primary endpoint data from the pivotal trial of BT-001, the company’s investigational prescription digital therapeutic platform.  



About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like